Cathy Bradley
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Employment | 40 | 2024 | 178 | 10.200 |
Why?
| | Neoplasms | 70 | 2024 | 2671 | 9.960 |
Why?
| | Medicaid | 37 | 2023 | 435 | 8.040 |
Why?
| | Breast Neoplasms | 49 | 2024 | 2253 | 5.570 |
Why?
| | Cancer Survivors | 16 | 2024 | 285 | 4.920 |
Why?
| | Insurance Coverage | 22 | 2024 | 230 | 4.500 |
Why?
| | Medicare | 36 | 2025 | 773 | 4.200 |
Why?
| | Insurance, Health | 20 | 2024 | 283 | 3.830 |
Why?
| | Cost of Illness | 14 | 2024 | 308 | 3.370 |
Why?
| | SEER Program | 22 | 2024 | 227 | 3.240 |
Why?
| | Poverty | 13 | 2022 | 521 | 2.950 |
Why?
| | Medically Uninsured | 12 | 2020 | 130 | 2.560 |
Why?
| | Colorectal Neoplasms | 16 | 2025 | 806 | 2.510 |
Why?
| | Healthcare Disparities | 14 | 2020 | 654 | 2.510 |
Why?
| | Health Services Accessibility | 18 | 2024 | 986 | 2.440 |
Why?
| | United States | 96 | 2025 | 14841 | 2.420 |
Why?
| | Uterine Cervical Neoplasms | 7 | 2020 | 257 | 2.370 |
Why?
| | Early Detection of Cancer | 10 | 2024 | 447 | 2.200 |
Why?
| | Survivors | 17 | 2022 | 493 | 2.190 |
Why?
| | Medical Oncology | 6 | 2024 | 289 | 2.140 |
Why?
| | Registries | 31 | 2023 | 2035 | 1.980 |
Why?
| | Health Benefit Plans, Employee | 5 | 2022 | 25 | 1.900 |
Why?
| | Health Care Costs | 14 | 2024 | 398 | 1.860 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 6 | 2025 | 1081 | 1.850 |
Why?
| | Antineoplastic Agents | 9 | 2025 | 2129 | 1.850 |
Why?
| | Humans | 202 | 2025 | 137585 | 1.820 |
Why?
| | Survivorship | 4 | 2022 | 52 | 1.650 |
Why?
| | Drug Costs | 4 | 2025 | 106 | 1.610 |
Why?
| | Caregivers | 6 | 2023 | 877 | 1.590 |
Why?
| | Health Care Reform | 4 | 2021 | 107 | 1.510 |
Why?
| | Lung Neoplasms | 11 | 2025 | 2526 | 1.490 |
Why?
| | Female | 128 | 2025 | 73304 | 1.330 |
Why?
| | Aged | 75 | 2025 | 23961 | 1.310 |
Why?
| | Colonic Neoplasms | 5 | 2016 | 258 | 1.310 |
Why?
| | Mental Health | 4 | 2023 | 726 | 1.230 |
Why?
| | Research | 6 | 2022 | 451 | 1.220 |
Why?
| | Policy | 4 | 2024 | 150 | 1.220 |
Why?
| | Michigan | 24 | 2015 | 109 | 1.210 |
Why?
| | Prostatic Neoplasms | 11 | 2022 | 1043 | 1.200 |
Why?
| | Socioeconomic Factors | 20 | 2022 | 1289 | 1.190 |
Why?
| | Middle Aged | 76 | 2024 | 33479 | 1.190 |
Why?
| | Prescription Drugs | 2 | 2023 | 109 | 1.150 |
Why?
| | Income | 8 | 2024 | 202 | 1.130 |
Why?
| | Efficiency | 7 | 2016 | 99 | 1.100 |
Why?
| | Neoplasm Staging | 17 | 2022 | 1389 | 1.100 |
Why?
| | Health Status | 10 | 2013 | 792 | 1.070 |
Why?
| | Male | 96 | 2025 | 67762 | 1.060 |
Why?
| | Aged, 80 and over | 37 | 2025 | 7635 | 1.050 |
Why?
| | Health Status Disparities | 2 | 2023 | 289 | 1.020 |
Why?
| | Medical Record Linkage | 2 | 2021 | 65 | 1.020 |
Why?
| | Papanicolaou Test | 2 | 2017 | 43 | 0.990 |
Why?
| | Adult | 66 | 2024 | 37929 | 0.960 |
Why?
| | Primary Health Care | 6 | 2023 | 1738 | 0.930 |
Why?
| | Motivation | 2 | 2020 | 570 | 0.900 |
Why?
| | Occupational Medicine | 1 | 2024 | 10 | 0.890 |
Why?
| | Cancer Care Facilities | 4 | 2024 | 38 | 0.890 |
Why?
| | Safety-net Providers | 3 | 2017 | 119 | 0.890 |
Why?
| | Patient Acceptance of Health Care | 4 | 2018 | 806 | 0.880 |
Why?
| | Medicare Part C | 1 | 2025 | 31 | 0.870 |
Why?
| | Communication | 3 | 2024 | 879 | 0.850 |
Why?
| | Eligibility Determination | 5 | 2018 | 65 | 0.840 |
Why?
| | Quality of Life | 8 | 2023 | 2892 | 0.830 |
Why?
| | Comorbidity | 12 | 2019 | 1622 | 0.820 |
Why?
| | Colonoscopy | 4 | 2019 | 245 | 0.800 |
Why?
| | Health Expenditures | 8 | 2023 | 189 | 0.790 |
Why?
| | Return to Work | 4 | 2022 | 21 | 0.780 |
Why?
| | Absenteeism | 4 | 2013 | 49 | 0.760 |
Why?
| | Mass Screening | 10 | 2022 | 1287 | 0.750 |
Why?
| | Virginia | 7 | 2018 | 62 | 0.740 |
Why?
| | Occupational Health | 1 | 2024 | 200 | 0.730 |
Why?
| | Focus Groups | 1 | 2024 | 522 | 0.720 |
Why?
| | Medication Adherence | 2 | 2023 | 467 | 0.720 |
Why?
| | Workplace | 4 | 2021 | 261 | 0.700 |
Why?
| | Mammography | 5 | 2024 | 154 | 0.680 |
Why?
| | Health Equity | 1 | 2022 | 99 | 0.670 |
Why?
| | Cost Sharing | 1 | 2020 | 15 | 0.650 |
Why?
| | Models, Economic | 2 | 2011 | 58 | 0.640 |
Why?
| | Information Dissemination | 1 | 2022 | 218 | 0.630 |
Why?
| | Perioperative Care | 1 | 2021 | 178 | 0.630 |
Why?
| | Chemotherapy, Adjuvant | 7 | 2023 | 389 | 0.610 |
Why?
| | Public Health | 1 | 2024 | 588 | 0.610 |
Why?
| | Preventive Health Services | 5 | 2023 | 148 | 0.600 |
Why?
| | Young Adult | 24 | 2024 | 13209 | 0.600 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.600 |
Why?
| | Retirement | 5 | 2022 | 31 | 0.600 |
Why?
| | Health Facilities | 1 | 2019 | 84 | 0.590 |
Why?
| | Spouses | 3 | 2017 | 105 | 0.580 |
Why?
| | Cost-Benefit Analysis | 9 | 2024 | 591 | 0.570 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 307 | 0.570 |
Why?
| | Diagnostic Imaging | 1 | 2020 | 332 | 0.560 |
Why?
| | Survival Analysis | 10 | 2019 | 1325 | 0.560 |
Why?
| | Reimbursement, Incentive | 1 | 2017 | 40 | 0.540 |
Why?
| | Healthy People Programs | 1 | 2016 | 8 | 0.510 |
Why?
| | Occupational Health Services | 2 | 2016 | 32 | 0.510 |
Why?
| | Bevacizumab | 1 | 2017 | 138 | 0.500 |
Why?
| | Job Satisfaction | 3 | 2013 | 218 | 0.500 |
Why?
| | Logistic Models | 13 | 2023 | 2074 | 0.500 |
Why?
| | Job Description | 2 | 2013 | 14 | 0.490 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 202 | 0.480 |
Why?
| | Massachusetts | 4 | 2021 | 172 | 0.480 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 622 | 0.480 |
Why?
| | Outpatients | 1 | 2019 | 396 | 0.480 |
Why?
| | Chronic Pain | 1 | 2019 | 262 | 0.470 |
Why?
| | Length of Stay | 6 | 2012 | 1215 | 0.470 |
Why?
| | Rectal Neoplasms | 1 | 2016 | 149 | 0.450 |
Why?
| | State Government | 3 | 2014 | 42 | 0.450 |
Why?
| | Fee-for-Service Plans | 4 | 2023 | 88 | 0.450 |
Why?
| | Vaginal Smears | 1 | 2014 | 57 | 0.440 |
Why?
| | Nursing Homes | 4 | 2013 | 181 | 0.440 |
Why?
| | Longitudinal Studies | 11 | 2022 | 2844 | 0.440 |
Why?
| | Emergency Treatment | 1 | 2015 | 118 | 0.420 |
Why?
| | Health Services Research | 4 | 2010 | 404 | 0.420 |
Why?
| | General Practice | 1 | 2014 | 29 | 0.420 |
Why?
| | Mouth Neoplasms | 3 | 2019 | 120 | 0.420 |
Why?
| | Sick Leave | 2 | 2019 | 13 | 0.410 |
Why?
| | Cross-Sectional Studies | 13 | 2023 | 5472 | 0.410 |
Why?
| | Delivery of Health Care | 5 | 2024 | 951 | 0.400 |
Why?
| | Health Personnel | 3 | 2022 | 710 | 0.400 |
Why?
| | Risk Factors | 15 | 2024 | 10388 | 0.400 |
Why?
| | Sickness Impact Profile | 1 | 2013 | 56 | 0.400 |
Why?
| | Behavioral Risk Factor Surveillance System | 4 | 2017 | 53 | 0.390 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2015 | 2531 | 0.390 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1692 | 0.390 |
Why?
| | Databases, Factual | 7 | 2021 | 1357 | 0.380 |
Why?
| | Insurance Claim Review | 2 | 2010 | 64 | 0.380 |
Why?
| | Marital Status | 3 | 2007 | 44 | 0.380 |
Why?
| | Value of Life | 2 | 2008 | 17 | 0.380 |
Why?
| | Homes for the Aged | 2 | 2013 | 34 | 0.380 |
Why?
| | Cohort Studies | 10 | 2025 | 5742 | 0.380 |
Why?
| | Work | 3 | 2010 | 18 | 0.370 |
Why?
| | Survival Rate | 7 | 2020 | 1972 | 0.370 |
Why?
| | Age Factors | 11 | 2022 | 3295 | 0.360 |
Why?
| | Neoplasm Metastasis | 3 | 2020 | 658 | 0.350 |
Why?
| | Health Services | 1 | 2012 | 107 | 0.350 |
Why?
| | Periodicals as Topic | 2 | 2023 | 211 | 0.340 |
Why?
| | Quality Improvement | 2 | 2018 | 1178 | 0.340 |
Why?
| | Hypoglycemia | 1 | 2015 | 445 | 0.340 |
Why?
| | Patient Protection and Affordable Care Act | 3 | 2024 | 103 | 0.340 |
Why?
| | Physician Self-Referral | 1 | 2010 | 1 | 0.340 |
Why?
| | Surgical Procedures, Operative | 2 | 2012 | 259 | 0.330 |
Why?
| | Social Class | 4 | 2022 | 282 | 0.330 |
Why?
| | Intestinal Perforation | 3 | 2016 | 46 | 0.330 |
Why?
| | Models, Econometric | 6 | 2017 | 34 | 0.320 |
Why?
| | Biomedical Research | 2 | 2020 | 692 | 0.320 |
Why?
| | Financing, Personal | 2 | 2019 | 26 | 0.320 |
Why?
| | Recovery of Function | 1 | 2013 | 653 | 0.310 |
Why?
| | Physicians | 1 | 2018 | 910 | 0.310 |
Why?
| | Radiation Oncology | 1 | 2010 | 82 | 0.310 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 213 | 0.310 |
Why?
| | Astrocytoma | 1 | 2010 | 128 | 0.310 |
Why?
| | Waiting Lists | 1 | 2011 | 266 | 0.310 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2016 | 132 | 0.310 |
Why?
| | Data Collection | 3 | 2014 | 673 | 0.310 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 683 | 0.310 |
Why?
| | Colorado | 3 | 2025 | 4565 | 0.300 |
Why?
| | Surveys and Questionnaires | 12 | 2018 | 5778 | 0.300 |
Why?
| | Administration, Oral | 2 | 2023 | 816 | 0.300 |
Why?
| | Dentists | 1 | 2008 | 20 | 0.300 |
Why?
| | Persuasive Communication | 1 | 2008 | 14 | 0.300 |
Why?
| | Dental Care | 1 | 2008 | 26 | 0.290 |
Why?
| | Propensity Score | 1 | 2010 | 294 | 0.290 |
Why?
| | Life Expectancy | 1 | 2008 | 69 | 0.290 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2018 | 63 | 0.290 |
Why?
| | Multivariate Analysis | 9 | 2019 | 1509 | 0.280 |
Why?
| | HIV Infections | 2 | 2022 | 2836 | 0.280 |
Why?
| | Odds Ratio | 9 | 2014 | 1070 | 0.280 |
Why?
| | Pneumonectomy | 1 | 2008 | 152 | 0.260 |
Why?
| | Patient Education as Topic | 1 | 2011 | 766 | 0.260 |
Why?
| | Likelihood Functions | 5 | 2021 | 144 | 0.250 |
Why?
| | Depression | 4 | 2021 | 1397 | 0.250 |
Why?
| | Confidence Intervals | 4 | 2013 | 329 | 0.250 |
Why?
| | Women, Working | 2 | 2002 | 12 | 0.250 |
Why?
| | Quality-Adjusted Life Years | 4 | 2017 | 113 | 0.240 |
Why?
| | Time Factors | 11 | 2013 | 6828 | 0.240 |
Why?
| | Online Systems | 1 | 2005 | 21 | 0.240 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 486 | 0.240 |
Why?
| | Treatment Outcome | 12 | 2019 | 10811 | 0.230 |
Why?
| | Forecasting | 6 | 2020 | 389 | 0.230 |
Why?
| | Colonic Diseases | 2 | 2016 | 33 | 0.230 |
Why?
| | Disability Evaluation | 1 | 2007 | 290 | 0.230 |
Why?
| | Myocardial Infarction | 3 | 2023 | 1046 | 0.230 |
Why?
| | Cost Savings | 2 | 2018 | 84 | 0.230 |
Why?
| | Cross Infection | 2 | 2017 | 256 | 0.230 |
Why?
| | Health Services Needs and Demand | 3 | 2017 | 273 | 0.220 |
Why?
| | Anxiety | 3 | 2021 | 1035 | 0.220 |
Why?
| | Referral and Consultation | 1 | 2010 | 786 | 0.220 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2011 | 630 | 0.220 |
Why?
| | Adolescent | 14 | 2024 | 21513 | 0.220 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 234 | 0.220 |
Why?
| | Needs Assessment | 2 | 2024 | 376 | 0.210 |
Why?
| | Models, Statistical | 4 | 2017 | 669 | 0.210 |
Why?
| | Physician-Patient Relations | 1 | 2008 | 548 | 0.210 |
Why?
| | Probability | 5 | 2023 | 304 | 0.210 |
Why?
| | Hospitals, Public | 1 | 2023 | 29 | 0.210 |
Why?
| | Substance-Related Disorders | 3 | 1997 | 1083 | 0.200 |
Why?
| | Head and Neck Neoplasms | 2 | 2019 | 606 | 0.200 |
Why?
| | Community-Based Participatory Research | 1 | 2024 | 162 | 0.200 |
Why?
| | Sex Factors | 6 | 2024 | 2071 | 0.200 |
Why?
| | Economics, Medical | 1 | 2022 | 6 | 0.200 |
Why?
| | Migraine Disorders | 1 | 2024 | 102 | 0.190 |
Why?
| | Hormones | 1 | 2023 | 143 | 0.190 |
Why?
| | Age Distribution | 4 | 2020 | 392 | 0.190 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 400 | 0.190 |
Why?
| | Salaries and Fringe Benefits | 1 | 2002 | 56 | 0.190 |
Why?
| | Ambulatory Care Facilities | 1 | 2024 | 232 | 0.190 |
Why?
| | Health Behavior | 2 | 2019 | 762 | 0.190 |
Why?
| | Carcinoma | 2 | 2017 | 240 | 0.190 |
Why?
| | Risk Assessment | 6 | 2022 | 3457 | 0.190 |
Why?
| | Colonic Polyps | 2 | 2014 | 88 | 0.190 |
Why?
| | Proportional Hazards Models | 5 | 2019 | 1266 | 0.190 |
Why?
| | Bisexuality | 1 | 2022 | 31 | 0.190 |
Why?
| | Food Supply | 1 | 2022 | 83 | 0.190 |
Why?
| | Hospital Charges | 3 | 2003 | 44 | 0.190 |
Why?
| | Incidence | 5 | 2022 | 2804 | 0.180 |
Why?
| | Hypoglycemic Agents | 3 | 2018 | 1291 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 1000 | 0.180 |
Why?
| | Insulin, Isophane | 1 | 2001 | 21 | 0.180 |
Why?
| | Intensive Care Units | 2 | 2017 | 827 | 0.180 |
Why?
| | Smoking | 2 | 2019 | 1627 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 1079 | 0.170 |
Why?
| | Evidence-Based Medicine | 2 | 2016 | 740 | 0.170 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1238 | 0.170 |
Why?
| | Retrospective Studies | 13 | 2024 | 15657 | 0.170 |
Why?
| | Exercise | 3 | 2023 | 2057 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2022 | 184 | 0.170 |
Why?
| | Internet | 1 | 2005 | 655 | 0.170 |
Why?
| | Decision Making | 2 | 2005 | 900 | 0.170 |
Why?
| | Kentucky | 1 | 2020 | 39 | 0.170 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 91 | 0.160 |
Why?
| | Hospitalization | 5 | 2016 | 2199 | 0.160 |
Why?
| | California | 2 | 2018 | 431 | 0.160 |
Why?
| | Sample Size | 1 | 2000 | 125 | 0.160 |
Why?
| | Population Surveillance | 2 | 2022 | 482 | 0.160 |
Why?
| | Carrier State | 2 | 2017 | 67 | 0.160 |
Why?
| | Benzodiazepines | 1 | 2021 | 155 | 0.160 |
Why?
| | Stress, Psychological | 2 | 2021 | 1100 | 0.160 |
Why?
| | Regression Analysis | 5 | 2021 | 1024 | 0.160 |
Why?
| | Ownership | 2 | 2010 | 94 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2023 | 956 | 0.150 |
Why?
| | Patient Care Team | 1 | 2024 | 631 | 0.150 |
Why?
| | Language Development Disorders | 1 | 2019 | 41 | 0.150 |
Why?
| | Patient Selection | 3 | 2010 | 696 | 0.150 |
Why?
| | Infection Control | 2 | 2017 | 167 | 0.150 |
Why?
| | Anthracyclines | 3 | 2023 | 42 | 0.150 |
Why?
| | Exercise Therapy | 1 | 2023 | 443 | 0.150 |
Why?
| | Los Angeles | 2 | 2015 | 76 | 0.150 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2023 | 49 | 0.150 |
Why?
| | Child | 7 | 2024 | 21935 | 0.150 |
Why?
| | Diabetes Mellitus | 3 | 2018 | 1040 | 0.150 |
Why?
| | Taxoids | 3 | 2023 | 102 | 0.150 |
Why?
| | Activities of Daily Living | 2 | 2010 | 413 | 0.150 |
Why?
| | Cancer Pain | 1 | 2018 | 29 | 0.140 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2019 | 220 | 0.140 |
Why?
| | Carboplatin | 1 | 2018 | 144 | 0.140 |
Why?
| | Cetuximab | 1 | 2018 | 98 | 0.140 |
Why?
| | Hyperlipidemias | 1 | 2019 | 120 | 0.140 |
Why?
| | Ireland | 2 | 2016 | 30 | 0.140 |
Why?
| | Stroke | 2 | 2024 | 1120 | 0.140 |
Why?
| | Infant, Newborn | 4 | 2020 | 6079 | 0.140 |
Why?
| | Accidental Falls | 1 | 2020 | 196 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 445 | 0.140 |
Why?
| | Unemployment | 2 | 2009 | 43 | 0.140 |
Why?
| | Financing, Government | 1 | 2017 | 47 | 0.140 |
Why?
| | Research Design | 4 | 2007 | 1139 | 0.140 |
Why?
| | Managed Care Programs | 1 | 2018 | 135 | 0.140 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 56 | 0.130 |
Why?
| | Inpatients | 2 | 2012 | 500 | 0.130 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1236 | 0.130 |
Why?
| | Hospital Costs | 2 | 2011 | 117 | 0.130 |
Why?
| | Public Health Practice | 1 | 2017 | 70 | 0.130 |
Why?
| | Patient Rights | 2 | 2019 | 13 | 0.130 |
Why?
| | Hypertension | 2 | 2024 | 1295 | 0.130 |
Why?
| | Patient Discharge | 1 | 2023 | 897 | 0.130 |
Why?
| | Psychiatric Department, Hospital | 1 | 1996 | 13 | 0.130 |
Why?
| | Attitude to Health | 3 | 2019 | 439 | 0.130 |
Why?
| | Cisplatin | 1 | 2018 | 320 | 0.130 |
Why?
| | Drug Therapy | 1 | 2017 | 85 | 0.130 |
Why?
| | Sex Distribution | 3 | 2020 | 375 | 0.130 |
Why?
| | Child Behavior | 1 | 1998 | 248 | 0.130 |
Why?
| | Heart Failure | 2 | 2023 | 2236 | 0.120 |
Why?
| | Language | 1 | 2019 | 292 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 491 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 396 | 0.120 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2016 | 66 | 0.120 |
Why?
| | Clinical Competence | 2 | 2014 | 1118 | 0.120 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 1996 | 24 | 0.120 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.120 |
Why?
| | Patient Admission | 1 | 1997 | 197 | 0.120 |
Why?
| | Colorectal Surgery | 1 | 2015 | 24 | 0.110 |
Why?
| | Child, Preschool | 4 | 2020 | 11074 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 266 | 0.110 |
Why?
| | Residence Characteristics | 2 | 2008 | 351 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 161 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2019 | 5131 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2024 | 3556 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 331 | 0.110 |
Why?
| | Child Development | 1 | 2019 | 475 | 0.110 |
Why?
| | Mastectomy, Segmental | 3 | 2009 | 93 | 0.110 |
Why?
| | National Health Programs | 1 | 2014 | 23 | 0.110 |
Why?
| | Infant | 3 | 2020 | 9465 | 0.110 |
Why?
| | Pennsylvania | 2 | 2024 | 116 | 0.110 |
Why?
| | Patient Satisfaction | 2 | 2013 | 660 | 0.110 |
Why?
| | Autism Spectrum Disorder | 1 | 2019 | 395 | 0.110 |
Why?
| | Systems Integration | 1 | 2013 | 37 | 0.100 |
Why?
| | Computer Simulation | 2 | 2023 | 978 | 0.100 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 96 | 0.100 |
Why?
| | Health Status Indicators | 1 | 2014 | 171 | 0.100 |
Why?
| | Pilot Projects | 3 | 2021 | 1710 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 889 | 0.100 |
Why?
| | Helping Behavior | 1 | 2013 | 18 | 0.100 |
Why?
| | Quality of Health Care | 2 | 2008 | 642 | 0.100 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.100 |
Why?
| | Occupations | 1 | 2012 | 49 | 0.100 |
Why?
| | Mandatory Programs | 1 | 2012 | 15 | 0.100 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1996 | 257 | 0.100 |
Why?
| | Insurance, Pharmaceutical Services | 1 | 2012 | 22 | 0.100 |
Why?
| | Pregnancy, Unwanted | 1 | 2012 | 14 | 0.100 |
Why?
| | Prospective Studies | 3 | 2017 | 7604 | 0.100 |
Why?
| | Maryland | 3 | 1997 | 60 | 0.100 |
Why?
| | Life Tables | 2 | 2008 | 20 | 0.100 |
Why?
| | Cost Control | 1 | 2012 | 39 | 0.090 |
Why?
| | Goals | 2 | 2023 | 170 | 0.090 |
Why?
| | Cause of Death | 1 | 2014 | 434 | 0.090 |
Why?
| | Self Disclosure | 1 | 2011 | 63 | 0.090 |
Why?
| | Community Health Services | 1 | 2013 | 227 | 0.090 |
Why?
| | Contraception Behavior | 1 | 2012 | 102 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 80 | 0.090 |
Why?
| | Retreatment | 1 | 2011 | 72 | 0.090 |
Why?
| | Educational Status | 1 | 2013 | 470 | 0.090 |
Why?
| | Sepsis | 1 | 2017 | 617 | 0.090 |
Why?
| | Mental Disorders | 2 | 1997 | 1077 | 0.090 |
Why?
| | Video Recording | 1 | 2011 | 180 | 0.090 |
Why?
| | Mastectomy | 1 | 2011 | 137 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 1996 | 527 | 0.090 |
Why?
| | Insulin | 1 | 2001 | 2409 | 0.080 |
Why?
| | Economics, Nursing | 1 | 2010 | 1 | 0.080 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 53 | 0.080 |
Why?
| | Stress, Physiological | 1 | 2013 | 443 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 556 | 0.080 |
Why?
| | Access to Information | 1 | 2010 | 49 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3284 | 0.080 |
Why?
| | Consumer Behavior | 1 | 1990 | 71 | 0.080 |
Why?
| | Standard of Care | 1 | 2010 | 72 | 0.080 |
Why?
| | Sentinel Surveillance | 1 | 2009 | 49 | 0.080 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 286 | 0.080 |
Why?
| | Occult Blood | 1 | 2009 | 34 | 0.080 |
Why?
| | Insurance Claim Reporting | 1 | 2009 | 24 | 0.080 |
Why?
| | Ohio | 1 | 2009 | 152 | 0.080 |
Why?
| | Comparative Effectiveness Research | 1 | 2010 | 152 | 0.080 |
Why?
| | Private Sector | 1 | 2009 | 52 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 578 | 0.080 |
Why?
| | Physical Exertion | 1 | 2010 | 215 | 0.080 |
Why?
| | Linear Models | 1 | 2011 | 849 | 0.080 |
Why?
| | Sex Characteristics | 2 | 2022 | 762 | 0.080 |
Why?
| | Home Nursing | 1 | 2008 | 25 | 0.080 |
Why?
| | Bias | 1 | 2010 | 218 | 0.080 |
Why?
| | Prevalence | 2 | 2020 | 2734 | 0.070 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2009 | 77 | 0.070 |
Why?
| | Women's Health | 2 | 2012 | 372 | 0.070 |
Why?
| | Psychometrics | 1 | 2013 | 720 | 0.070 |
Why?
| | Reimbursement Mechanisms | 1 | 2009 | 85 | 0.070 |
Why?
| | Education, Professional | 1 | 2008 | 17 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2010 | 363 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2010 | 565 | 0.070 |
Why?
| | Pain | 2 | 2010 | 756 | 0.070 |
Why?
| | Radiotherapy | 1 | 2008 | 201 | 0.070 |
Why?
| | Self Care | 1 | 2010 | 380 | 0.070 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 530 | 0.070 |
Why?
| | Leukemia | 1 | 2008 | 240 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 496 | 0.060 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 1040 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2006 | 128 | 0.060 |
Why?
| | Lung Diseases | 1 | 2012 | 767 | 0.060 |
Why?
| | Charities | 1 | 2005 | 9 | 0.060 |
Why?
| | Empirical Research | 1 | 2005 | 21 | 0.060 |
Why?
| | Hospice Care | 1 | 2007 | 202 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2001 | 3715 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 1477 | 0.050 |
Why?
| | Diagnosis-Related Groups | 1 | 2003 | 31 | 0.050 |
Why?
| | Florida | 2 | 2014 | 107 | 0.050 |
Why?
| | Resource Allocation | 1 | 2003 | 52 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1639 | 0.050 |
Why?
| | Causality | 1 | 2023 | 126 | 0.050 |
Why?
| | Health Surveys | 2 | 2007 | 514 | 0.050 |
Why?
| | Social Security | 1 | 2002 | 5 | 0.050 |
Why?
| | Selection Bias | 1 | 2002 | 37 | 0.050 |
Why?
| | Markov Chains | 2 | 2017 | 126 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 718 | 0.050 |
Why?
| | Sampling Studies | 1 | 2002 | 99 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2005 | 786 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2001 | 4 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2002 | 110 | 0.040 |
Why?
| | Insulin, Long-Acting | 1 | 2001 | 63 | 0.040 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 333 | 0.040 |
Why?
| | Palliative Care | 1 | 2007 | 758 | 0.040 |
Why?
| | Family Characteristics | 1 | 2002 | 191 | 0.040 |
Why?
| | Insulin Glargine | 1 | 2001 | 84 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 938 | 0.040 |
Why?
| | Normal Distribution | 1 | 2000 | 21 | 0.040 |
Why?
| | Drug Evaluation | 1 | 2000 | 84 | 0.040 |
Why?
| | Diffusion of Innovation | 1 | 2001 | 99 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2828 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2004 | 1050 | 0.040 |
Why?
| | Nursing Research | 1 | 2000 | 50 | 0.040 |
Why?
| | Presenteeism | 1 | 2019 | 7 | 0.040 |
Why?
| | Etidronic Acid | 1 | 1998 | 5 | 0.040 |
Why?
| | Alendronate | 1 | 1998 | 15 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 28 | 0.040 |
Why?
| | Informed Consent | 1 | 2000 | 175 | 0.040 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 1998 | 42 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 436 | 0.040 |
Why?
| | Spinal Fractures | 1 | 1998 | 73 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 14 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2019 | 171 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2001 | 347 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 146 | 0.030 |
Why?
| | Tennessee | 1 | 2017 | 44 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 352 | 0.030 |
Why?
| | Smoking Prevention | 1 | 1998 | 184 | 0.030 |
Why?
| | Puberty | 1 | 1998 | 146 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 596 | 0.030 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 1997 | 36 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2018 | 225 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 19 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 189 | 0.030 |
Why?
| | Utilization Review | 1 | 1996 | 36 | 0.030 |
Why?
| | Alzheimer Disease | 1 | 2002 | 560 | 0.030 |
Why?
| | Patient Dropouts | 1 | 1997 | 67 | 0.030 |
Why?
| | Arizona | 1 | 1996 | 81 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 60 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 73 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 786 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2018 | 176 | 0.030 |
Why?
| | Catheter-Related Infections | 1 | 2017 | 92 | 0.030 |
Why?
| | Anticholesteremic Agents | 1 | 2018 | 153 | 0.030 |
Why?
| | Health Policy | 1 | 2019 | 388 | 0.030 |
Why?
| | Schools | 1 | 2000 | 461 | 0.030 |
Why?
| | Hospitals, Community | 1 | 1996 | 52 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1996 | 36 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Health Resources | 2 | 2009 | 120 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2018 | 494 | 0.030 |
Why?
| | Telemedicine | 1 | 2023 | 862 | 0.030 |
Why?
| | Protoporphyrins | 1 | 1993 | 16 | 0.030 |
Why?
| | Acute Disease | 1 | 1996 | 1007 | 0.030 |
Why?
| | Learning Curve | 1 | 2014 | 72 | 0.030 |
Why?
| | Lead | 1 | 1993 | 64 | 0.030 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 515 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1738 | 0.020 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1946 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1199 | 0.020 |
Why?
| | Community Participation | 1 | 2013 | 131 | 0.020 |
Why?
| | Societies, Medical | 1 | 2016 | 820 | 0.020 |
Why?
| | Risk | 1 | 2014 | 912 | 0.020 |
Why?
| | General Surgery | 1 | 2014 | 173 | 0.020 |
Why?
| | Gastroenterology | 1 | 2014 | 180 | 0.020 |
Why?
| | Pregnancy | 2 | 2012 | 6763 | 0.020 |
Why?
| | Hepatitis B | 1 | 1991 | 70 | 0.020 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 11 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 451 | 0.020 |
Why?
| | Contraception | 1 | 2012 | 161 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4030 | 0.020 |
Why?
| | Budgets | 1 | 2009 | 13 | 0.020 |
Why?
| | Sigmoidoscopy | 1 | 2009 | 12 | 0.020 |
Why?
| | Leadership | 1 | 2013 | 388 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2010 | 183 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2013 | 546 | 0.020 |
Why?
| | Prostatectomy | 1 | 2009 | 104 | 0.020 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 186 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 518 | 0.020 |
Why?
| | Occupational Exposure | 1 | 1991 | 341 | 0.020 |
Why?
| | Psychology | 1 | 2008 | 85 | 0.020 |
Why?
| | Demography | 1 | 2008 | 291 | 0.020 |
Why?
| | Lifting | 1 | 2006 | 4 | 0.020 |
Why?
| | Least-Squares Analysis | 1 | 2006 | 79 | 0.020 |
Why?
| | Mortality | 1 | 2008 | 362 | 0.020 |
Why?
| | Illinois | 1 | 2006 | 43 | 0.020 |
Why?
| | Telephone | 1 | 2007 | 173 | 0.020 |
Why?
| | Body Weight | 1 | 1990 | 985 | 0.020 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.010 |
Why?
| | Prejudice | 1 | 2006 | 73 | 0.010 |
Why?
| | Burnout, Professional | 1 | 2010 | 442 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2003 | 73 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 431 | 0.010 |
Why?
| | Vaccination | 1 | 1991 | 1381 | 0.010 |
Why?
| | Behavior | 1 | 2002 | 90 | 0.010 |
Why?
| | Episode of Care | 1 | 2001 | 8 | 0.010 |
Why?
| | Decision Trees | 1 | 2001 | 93 | 0.010 |
Why?
| | Drug Prescriptions | 1 | 2002 | 245 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2003 | 530 | 0.010 |
Why?
| | Reoperation | 1 | 2001 | 573 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2002 | 1023 | 0.010 |
Why?
| | Estrogens | 1 | 1998 | 367 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1998 | 1066 | 0.010 |
Why?
| | Estradiol | 1 | 1998 | 521 | 0.010 |
Why?
| | Lead Poisoning | 1 | 1993 | 19 | 0.010 |
Why?
| | Reference Values | 1 | 1993 | 816 | 0.010 |
Why?
| | ROC Curve | 1 | 1993 | 554 | 0.010 |
Why?
| | Program Evaluation | 1 | 1991 | 898 | 0.000 |
Why?
|
|
Bradley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|